Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer
MONDAY, April 20, 2020 -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | General Medicine | HER2 | Herceptin | Xeloda